

32-20660: Recombinant Human IGF-BP6(Discontinued)

Alternative Name : Insulin-like Growth Factor-Binding Protein 6, IBP-6

Description

Source:(BTI-Tn-5B1-4) Hi-5 Insect cells

IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6, which specifically inhibits IGF-II actions, is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant Human IGF-BP6 has a calculated mass of 22.3 kDa and consists of 213 amino acid residues, including the IGF-BP domain and thyroglobulin type-I domain. Recombinant Human IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.

Product Info

Amount : 5 µg / 20 µg

Purification : Purity: >= 95% by SDS-PAGE gel and HPLC analyses.

Content : This recombinant protein is supplied in lyophilized form.

Amino Acid : RCPGCGQGVQ AGCPGGCVVE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP
KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP
SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLV PNCDHARGFYR KRQCRSSQGG
RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG

Application Note

Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED_{50} for this effect is 0.1 – 0.4 µg/ml.